Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | SQLE | Q14534 | 7/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18034142 | 1.00 | KMT2A (0.41) | KMT2ASQLEALOX15CYP3A4MAPT | |
| SCHEMBL18022145 | 0.79 | ALDH1A1 (0.43) | KMT2ASQLEALOX15CYP3A4MAPT | |
| SCHEMBL18022192 | 0.77 | KMT2A (0.50) | KMT2ASQLEALOX15CYP3A4MAPT | |
| SCHEMBL18022146 | 0.77 | KMT2A (0.50) | KMT2ASQLEALOX15CYP3A4MAPT | |
| SCHEMBL18034098 | 0.77 | KMT2A (0.50) | KMT2ASQLEALOX15CYP3A4MAPT | |
| SCHEMBL18022162 | 0.76 | KMT2A (0.48) | KMT2ASQLEALOX15CYP3A4MAPT | |
| SCHEMBL18034144 | 0.76 | — | — | |
| SCHEMBL18022164 | 0.74 | KMT2A (0.46) | KMT2ASQLEALOX15CYP3A4MAPT | |
| SCHEMBL18022150 | 0.74 | KMT2A (0.38) | KMT2ASQLEALOX15CYP3A4MAPT | |
| SCHEMBL18022158 | 0.72 | ALDH1A1 (0.37) | KMT2ASQLEALOX15CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016133940-A1 | ANTICANCER AGENTS AND PROCESS OF MAKING THEREOF | GOLDEN BIOTECHNOLOGY CORPORATION (US) | 2016-08-25 | — | — | WO | disclosed |
| US-20160237012-A1 | ANTICANCER AGENTS AND PROCESS OF MAKING THEREOF | GOLDEN BIOTECHNOLOGY CORPORATION | 2016-08-18 | — | — | US | disclosed |
| US-20160237012-A1 | ANTICANCER AGENTS AND PROCESS OF MAKING THEREOF | GOLDEN BIOTECHNOLOGY CORPORATION | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237012-A1 | ANTICANCER AGENTS AND PROCESS OF MAKING THEREOF | MCL1, HCCS, CASP3 | KMT2A 3237/4885SQLE 70/4885ALOX15 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.